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Chorioamnionitis, neuroinflammation,
and injury: timing is key in the preterm
ovine fetus
Ruth Gussenhoven1,2, Rob J. J. Westerlaken1, Daan R. M. G. Ophelders1,3, Alan H. Jobe4, Matthew W. Kemp5,
Suhas G. Kallapur4, Luc J. Zimmermann1,3, Per T. Sangild6,7, Stanislava Pankratova6,7, Pierre Gressens8,9,10,
Boris W. Kramer1,2,3, Bobbi Fleiss8,9,10 and Tim G. A. M. Wolfs1,3,11*
Abstract
Background: Antenatal infection (i.e., chorioamnionitis) is an important risk factor for adverse neurodevelopmental
outcomes after preterm birth. Destructive and developmental disturbances of the white matter are hallmarks of
preterm brain injury. Understanding the temporal effects of antenatal infection in relation to the onset of neurological
injury is crucial for the development of neurotherapeutics for preterm infants. However, these dynamics remain unstudied.
Methods: Time-mated ewes were intra-amniotically injected with lipopolysaccharide at 5, 12, or 24 h or 2, 4, 8, or 15 days
before preterm delivery at 125 days gestational age (term ~ 150 days). Post mortem analyses for peripheral immune
activation, neuroinflammation, and white matter/neuronal injury were performed. Moreover, considering the
neuroprotective potential of erythropoietin (EPO) for perinatal brain injury, we evaluated (phosphorylated) EPO
receptor (pEPOR) expression in the fetal brain following LPS exposure.
Results: Intra-amniotic exposure to this single bolus of LPS resulted in a biphasic systemic IL-6 and IL-8 response.
In the developing brain, intra-amniotic LPS exposure induces a persistent microgliosis (IBA-1 immunoreactivity)
but a shorter-lived increase in the pro-inflammatory marker COX-2. Cell death (caspase-3 immunoreactivity) was
only observed when LPS exposure was greater than 8 days in the white matter, and there was a reduction in the
number of (pre) oligodendrocytes (Olig2- and PDGFRα-positive cells) within the white matter at 15 days post LPS
exposure only. pEPOR expression displayed a striking biphasic regulation following LPS exposure which may help
explain contradicting results among clinical trials that tested EPO for the prevention of preterm brain injury.
Conclusion: We provide increased understanding of the spatiotemporal pathophysiological changes in the preterm
brain following intra-amniotic inflammation which may aid development of new interventions or implement interventions
more effectively to prevent perinatal brain damage.
Keywords: Chorioamnionitis, Fetal, Preterm, Sheep, Inflammation, Brain injury, Erythropoietin, EPO receptor
Background
Antenatal infections (i.e., chorioamnionitis) are an
important risk factor for preterm birth and a major con-
tributor to neonatal morbidity and mortality [1, 2].
Intra-amniotic exposure to microorganisms and subse-
quent induction of inflammatory mediators in the
amniotic cavity can initiate a fetal systemic immune
response that is characterized by increased plasma inter-
leukin (IL)-6 and IL-8 concentrations [3], and (persist-
ent) changes in essential immunological organs
including the fetal spleen and thymus [4, 5]. At the
crosstalk between fetal peripheral blood and the brain (i.
e., blood-brain barrier), this systemic inflammatory
response can initiate a detrimental neuroinflammatory
response which is primarily mediated by microglia and
peripheral immune effector cells [6, 5]. This cerebral
inflammatory response is a risk factor for preterm brain
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injury and concomitant adverse neurodevelopmental
outcomes including cognitive, behavioral, and atten-
tional impairments and motor dysfunctions (i.e., cere-
bral palsy) [7, 5].
In a pre-clinical chorioamnionitis model, we showed
that short-term (2 days) intra-amniotic exposure to lipo-
polysaccharide (LPS) resulted in systemic inflammation,
overt microgliosis, and changes in myelin basic protein
(MBP) immunoreactivity (IR) in the fetal ovine brain [8].
However, this systemic and cerebral phenotype was sub-
stantially different following longer exposure time (7 days)
indicating that time-dependent peripheral and cerebral
changes occur following intra-amniotic inflammation.
Moreover, we and others have shown that inflammation
can modulate a second inflammatory stimulus through ei-
ther preconditioning or sensitization of the fetal brain [9,
8, 10]. Taken together, this emphasizes that inflammation
as pathogenic mediator for brain damage is not a single
trigger within a short time frame but more a dynamic
process over an extended period of time. Therefore, de-
tailed studies elucidating the time-dependent effects of
antenatal infection/inflammation in relation to neuro-
logical injury and development are crucial to gain insight
in the pathophysiological changes in the fetal brain follow-
ing antenatal stress. Importantly, such temporal insight in
the induction of brain injury following antenatal stress is
also essential to define the therapeutic window of oppor-
tunity for neurotherapeutics.
One of the most promising treatment options for pre-
term neonates at high risk for brain injury is erythropoi-
etin (EPO), an important cytokine for brain development
[11, 12]. Multiple experimental and clinical studies have
demonstrated efficacy of EPO administration to prevent
injury to the preterm brain, including severe periventricu-
lar leukomalacia, without adverse effects [13–21]. In con-
trast, other clinical trials do not report improvement in
neurodevelopment following EPO treatment [22, 23].
Effects of EPO are mediated by its receptor, which is
abundantly present on (pre) oligodendrocytes, astrocytes,
microglia, and neurons. EPO binding triggers phosphoryl-
ation of two monomers, which in turn phosphorylates and
activates the signaling kinase Jak-2 facilitating effects in-
cluding its anti-inflammatory, anti-oxidative, and anti-
apoptotic properties [24, 25]. In addition, EPO enhances
neuro- and oligodendrogenesis, oligodendrocyte matur-
ation, and myelin production which are indispensable
events in injury repair and normal neurodevelopment
[26]. We hypothesize that changes in basal levels of EPO
receptor activation in response to inflammation or peri-
natal stress might explain at least part of the differences in
clinical outcomes following EPO treatment.
Considering the clinical need for understanding the
time-dependent cerebral changes following intra-
amniotic inflammation, we performed a detailed analysis
of the temporal dynamics of intra-amniotic LPS-induced
systemic and cerebral inflammation and subsequent fetal
brain injury. In addition, to optimize EPO treatment in
the clinical setting, we analyzed the temporal expression
of the phosphorylated EPO receptor (pEPOR) in the
course of intra-amniotic inflammation.
Methods
Study approval
Animal procedures were performed with approval of the
animal ethics committee of the University of Western
Australia (Perth, Australia).
Experimental design
The design of this study was published previously [4].
Briefly, 52 time-mated ewes with singleton fetuses were
randomly allocated in groups of 5–7 animals per group
to receive an intra-amniotic injection under ultrasound
guidance with an established dose [27] of 10 mg Escheri-
chia coli-derived LPS (O55:B5; Sigma-Aldrich, St. Louis,
MO) at 5, 12, or 24 h or 2, 4, 8, or 15 days before pre-
term delivery at 125 days of gestation (term ~ 150 days)
(Fig. 1). This paradigm is based on the clinical paradigm,
where we know the gestational age of the infant but not
the length of exposure to inflammation. As such, all our
tissues were collected at a known gestation age but in-
flammation was induced at various times before. The
half-life time of LPS in the amniotic fluid is relatively
long (1.7 days) and LPS concentrations remain detect-
able till 15 days after injection [28]. Moreover, intra-
amniotic delivery of 0.1 mg LPS, a bolus which in this
study is reached at 10 days after injection, still results in
an influx of inflammatory cells in the amniotic fluid and
fetal lungs [27] indicating that IA delivery of 10 mg LPS
Fig. 1 Study design. Pregnant ewes received an intra-amniotic injection with 10 mg Escherichia coli-derived lipopolysaccharide (LPS) at 5, 12, or
24 h or 2, 4, 8, or 15 days (black arrows) before preterm delivery at 122 days of gestation (term ~ 150 days). Control animals received an intra-amniotic
injection with an equivalent volume of 0.9% saline solution at comparable time points to LPS injections
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is a clinical relevant ongoing inflammatory stimulus.
Fetuses of either sex were used, and previous analysis of
the thymus reported no sex specific differences in this
model [4]. Control animals received an equivalent vol-
ume of 0.9% saline solution (SAL; controls) at variable
gestational ages comparable to LPS injections, ranging
from 5 h to 15 days before preterm delivery. Within this
control group, no differences were observed between dif-
ferent lengths of saline exposure for which we have
pooled these animals in one control group (SAL). At
125 days of gestation, when ovine brain development is
similar to 32–34 weeks of human gestation [29], all fe-
tuses were surgically delivered and immediately eutha-
nized with intravenous pentobarbitone (100 mg/kg).
Fetal blood was collected and the brains were removed
and immersion fixed in 4% paraformaldehyde.
Analysis of blood IL-6 and IL-8 concentration
Levels of the pro-inflammatory cytokines interleukin
(IL)-6 and IL-8 were measured in fetal plasma as
markers for systemic inflammation using ovine-specific
sandwich enzyme-linked immunosorbent assays (ELISA)
as previously described [8].
In short, a 96-wells plate was coated with a monoclo-
nal mouse-anti IL-6 (Millipore Cat# MAB1004, working
concentration 1:200) or IL-8 (Millipore Cat# MAB1044,
working concentration 1:200) and incubated overnight
at 4 °C. The standard curve and serum samples were di-
luted in PBS + 0.1% BSA in 1:1 or 1:80, respectively, for
IL-6 and IL-8. Incubation with the detection antibody
rabbit-anti-ovine IL-6 (Millipore Cat# AB1839, working
concentration 1:500) or IL-8 (AB1040, Millipore, work-
ing concentration 1:500) was performed for 1 h, followed
by incubation with a HRP-labeled antibody (Jackson
ImmunoResearch Labs Cat# 111-035-045, working con-
centration 1:500). Next, incubation with 3,3′5,5′-tetra-
methylbenzidine (TMB) substrate solution was done for
10 (IL-6) or 2,5 (IL-8) minutes. The reaction was
stopped by addition of H2SO4, and the optical density
(OD) was measured at 450 nm in a Thermo Electron
Type 1500 Multiskan Spectrum Microplate Reader.
Concentrations were expressed relative to a standard
curve of recombinant ovine IL-6 or IL-8 (Immuno-
Chemistry Technologies, Bloomington, MN, USA).
Histology and immunohistochemistry
The cerebral white matter and hippocampus are most
commonly affected by intra-amniotic infections at this
developmental stage [30]. Therefore, we have chosen to
assess inflammatory and structural changes within these
regions of interest. After fixation, a predefined region
containing the posterior hippocampus/mid-thalamus of
the left hemisphere was embedded in paraffin and serial
coronal sections (4 μm) were cut with a Leica RM2235
microtome. Hematoxylin and eosin (H&E) staining was
performed for structural and morphological analysis.
Immunohistochemical staining was performed on four
slides per staining per animal (every 10th consecutive
slide) as previously reported [8]. Inflammatory changes
were assessed by the following immunohistochemical
markers: cylcooxygenase-2 (COX-2) (1:50, Cayman
Chemical; aa570-598), ionized calcium-binding adapter
molecule 1 (IBA-1) (1:1000, Wako Pure Chemical Indus-
tries, Osaka, Japan), and glial fibrillary acidic protein
(GFAP) (1:1000, DAKO Z0334). The presence of neutro-
phils was assessed by myeloperoxidase (MPO) staining
(1:200, DAKO A0398). Markers used to assess alter-
ations in the white matter including oligodendrocyte dif-
ferentiation were oligodendrocyte transcription factor 2
(Olig2) (1:200, Millipore, 13 AB9610), platelet-derived
growth factor receptor alpha (PDGFRa) (1:100, Santa
Cruz Biotechnology, sc338), 2′,3′-cyclic-nucleotide 3′-
phosphodiesterase (CNPase) (1:1000, Sigma, C5922),
and myelin basic protein (MBP) (1:1000, Merck Milli-
pore, MAB386). Neuronal architecture, including cell
bodies and dendrites, was determined by microtubule-
associated protein-2 (MAP-2) (1:500, Sigma, M9942).
Apoptotic cell death was measured as cells positive for
cleaved caspase-3 (1:1000, cell signaling, #9661), and the
number of mitotic cells were identified by phospho-
Histone H3 (pHH3) (1:100, Santa Cruz Biotechnology,
sc-101,679). The presence of the erythropoietin receptor
was assessed by measuring the expression of the (phos-
phorylated) erythropoietin receptor (EPOR and pEPOR)
(1:200, Santa Cruz, SC-365662 and SC-20236).
Deparaffinization and rehydration was performed by
incubation in xylol and decreasing alcohol concentra-
tions. Endogenous peroxidase activity was quenched via
incubation with 0.3% H2O2 for 10 min. Antigen retrieval
involved boiling tissues in citrate buffer (pH 6.0) for
10 min or for pEPOR proteinase K at 37 °C for 5 min.
Nonspecific binding was prevented by incubation with
5% (IBA-1, GFAP, MAP2, pHH3) or 10% (MPO,
CNPase) normal goat serum, 5% bovine serum albumin
(COX-2, MBP, Olig2, EPOR) (Invitrogen Thermofisher
Scientific), or 10% nonfat dry milk (pEPOR; Elk, Cam-
pina bv., Eindhoven, The Netherlands) for 1 h. Tissues
were incubated with the primary antibody overnight at
4 °C, followed by incubation with the species specific
secondary antibody at 1:200 (DAKO) for 1 h at room
temperature. The antibody-specific signal was enhanced
with a Vectastain ABC peroxidase Elite kit (Vector
Laboratories Inc., Burlingame, CA) for 1 h and 3,3′-
diaminobenzide (COX-2, IBA-1, GFAP, MPO,
PDGFRa, CNPase, MBP, MAP-2, pHH3, EPOR) or
nickel chloride 3,3′-diaminobenzide (Olig2, cleaved
caspase-3, pEPOR) for 2–10 min. Nuclei were stained
with Mayer’s hematoxylin.
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Qualitative and quantitative analysis
An independent neuropathologist and two independent
researchers who were blinded for the experimental condi-
tions performed qualitative and quantitative analysis of
the tissues. Analysis was performed using a light micro-
scope (Leica DM2000) equipped with Leica QWin Pro
version 3.4.0 software (Leica Microsystems, Mannheim,
Germany). H&E-stained sections were scored for gliosis,
hemorrhages, and structural damage-like cyst formation.
Regions of interest of the white matter and hippocampus
were defined as previously described [31]. In addition, gray
matter alterations in the cerebral cortex were assessed
within the same section. Three to five adjacent images
were taken per region of interest at × 100 magnification,
and analyses were performed using Leica Qwin Pro v3.4.0.
software (Leica Microsystems, Wetzlar, Germany). Area
fractions and integrated densities were calculated for
IBA-1, GFAP, COX-2, MBP, MAP-2, and pEPOR. MPO,
Olig2, PDGFRa, CNPase, pHH3, and cleaved caspase-3-
positive cells were counted and expressed as total cell
count per square millimeter (cells/mm2). In addition,
MPO+ cells were also counted in the choroid plexus.
Values per region of interest were averaged.
Statistical analysis
All values are shown as mean with 95% confidence inter-
val (CI) or standard deviations (SD). Comparison between
different experimental groups was performed with analysis
of variance (ANOVA) or with a random intercept-mixed
model in case of repeated measurements per animal (e.g.,
different sections per brain) with Bonferroni correction
for multiple comparisons. We applied log transformation
to obtain normal distributed data when data or variables
were positively skewed before statistical testing. Statistical
analysis was performed with IBM SPSS Statistics Version
22.0 (IBM Corp., Armonk, NY, USA; SPSS). Statistical
significance was accepted at p < 0.05. Considering the rela-
tively low number of animals per group, exact p values are
provided and 0.05 < p < 0.1 is considered a trend.
Results
Animal characteristics
At birth, no differences in weight were found between
experimental groups. Fetal blood pH and hemoglobin
levels did not differ following intra-amniotic LPS expos-
ure. No sex differences in susceptibility were observed in
either readout including animal characteristics and all
following readouts regarding systemic cytokine levels
and immunohistochemical analysis.
Intra-amniotic LPS exposure results in a biphasic fetal
systemic inflammatory response
Intra-amniotic exposure to LPS results in an acute in-
crease of fetal systemic IL-6 concentrations at 5, 12,
and 24 h after LPS exposure compared to control
levels (SAL vs 5 h LPS p = 0.0157; SAL vs 12 h LPS
p = 0.0011; SAL vs 24 h LPS p = 0.0035) (Fig. 2a).
Subsequently, at 4 and 8 days after LPS exposure,
systemic IL-8 concentrations are increased compared
to controls (SAL vs. 4 days LPS p = 0.0147; SAL vs.
8 days LPS p = 0.0502) (Fig. 2b).
Cerebral inflammation in the fetal white matter,
hippocampus, and cortex following intra-amniotic LPS
exposure
A systemic fetal inflammatory response is postulated to
initiate cerebral inflammation leading to subsequent in-
jury [32–34]. Therefore, we initially measured markers
of changes in neuroinflammatory processes (IBA-1,
COX-2, GFAP). We found that the systemic inflamma-
tory response following intra-amniotic LPS exposure is
followed by cerebral inflammatory changes as indicated
by an increase in IBA-1 IR in the white matter at 12 h,
2 days, 4 days, and 8 days following LPS exposure com-
pared to controls (SAL vs. 12 h LPS p = 0.012; SAL vs.
Fig. 2 a–b Circulatory interleukin (IL)-6 and IL-8 concentrations illustrate
a biphasic response following intra-amniotic LPS exposure. Undetectable
values were assigned an arbitrary value of 1 pg/mL in order to perform
statistical analysis. Statistical analysis was done with ANOVA, and values
are expressed as mean ± 95% CI. Asterisk indicated p< 0.05 versus
control group; number sign indicated 0.05 < p< 0.1 versus control
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2 days LPS p = 0.006; SAL vs. 4 days LPS p = 0.005; SAL
vs. 8 days LPS p = 0.088) (Fig. 3a, b). In the hippocam-
pus, inflammation is detected by an acute increase in
COX-2 IR at 5, 12, and 24 h post LPS exposure (SAL vs.
5 h LPS p = 0.055; SAL vs. 12 h LPS p = 0.016; SAL vs.
24 h LPS p = 0.096) (Fig. 3c, d) and an increase in IBA-1
IR at 15 days after LPS exposure compared to controls
(SAL vs. 15 days LPS p = 0.073). There were no changes
of GFAP IR after LPS exposure at any of the time points.
As outlined in Table 1, the number of MPO+ cells is in-
creased in the white matter at 15 days post LPS expos-
ure (SAL vs. 15 days LPS p = 0,027). In the choroid
plexus, no significant differences of MPO+ cells were
found between groups (Table 1).
Cell death and proliferation in the fetal white matter,
hippocampus, and cortex following intra-amniotic LPS
exposure
To assess whether cerebral inflammation is followed by
tissue injury, we measured the number of caspase-3-
positive cells in the cerebral white matter, hippocampus,
and cortex as a marker of apoptotic cell death as this is
an important prognostic factor for neurological out-
comes [35]. Exposure to LPS results in an increase in
cleaved caspase-3-positive cells in the white matter at
8 days following LPS exposure (SAL vs 8 days LPS p = 0.
004), in the hippocampus at 2, 4, 8, and 15 days follow-
ing LPS exposure (SAL vs 2 days LPS p = 0.002; SAL vs
4 days LPS p = 0.030; SAL vs 8 days LPS p = 0.058; SAL
Fig. 3 Intra-amniotic exposure to LPS induces an acute, transient cerebral inflammatory response in the preterm white matter and hippocampus.
An increase of the area fraction of IBA-1 immunoreactivity (IR) was observed in the white matter at 12 h, 2 days, 4 days, and 8 days following LPS
exposure compared to controls (SAL vs. 12 h LPS p = 0.012; SAL vs. 2 days LPS p = 0.006; SAL vs. 4 days LPS p = 0.005; SAL vs. 8 days LPS p = 0.088)
(a, b). In the hippocampus, an increase of the area fraction of COX-2 IR was found at 5, 12, and 24 h following LPS exposure (SAL vs. 5 h LPS p = 0.055;
SAL vs. 12 h LPS p = 0.016; SAL vs. 24 h LPS p = 0.096) (c, d). Representative histological figures of the IBA-1-positive microglia in animals exposed to
intra-amniotic saline (SAL), 2, 8, and 15 days of LPS are shown in a. Representative histological figures of COX-2-positive neurons in the hippocampus
of animals exposed to saline (SAL), 12 h, 2 days, and 15 days LPS are depicted in (d). IBA-1 IR and COX-2 IR are depicted as mean % area fraction ±
95% CI. Asterisk indicated p < 0.05 versus control (SAL); number sign indicated 0.05 < p < 0.1 versus control (SAL). Images taken at × 100 magnification
(insert at × 400 magnification), scale bar = 200 μm
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vs 15 days LPS p = 0.042) and in the cortex at 8 days fol-
lowing LPS exposure (SAL vs 8 days LPS p = 0.041)
compared to controls (Fig. 4a, b). No evidence of struc-
tural changes such as intraventricular hemorrhages and
cystic lesions in all experimental groups was found. To
assess the proliferation state of the brain, pHH3+ cells
were counted. At 2 days following LPS exposure, a trend
towards significant decrease in pHH3+ cells was found
(SAL vs. 2 days LPS p = 0.100) (Fig. 4c).
Distinct time-dependent changes in numbers of
oligodendrocyte lineage cells following LPS exposure
The typical histopathological substrate of brain injury in
premature infants consists of injury of the developing
oligodendrocyte (OL), a cell type that is abundantly
present within the brain during weeks 23–32 of gesta-
tion (when preterm birth often occurs) and is prone to
inflammatory insults [36]. Therefore, we have assessed
oligodendrocyte development following intra-amniotic
LPS exposure by studying the following oligodendrocyte
lineage markers: Olig-2 as a pan-oligodendrocyte lineage
marker, PDGFRα as a pre-oligodendrocyte marker (for
both OL progenitor and pre-OLs), CNPase as an early
oligodendrocyte differentiation marker, and MBP for
mature oligodendrocytes and myelin. At 15 days after
LPS exposure, a significant decrease in Olig2+ cell num-
ber was found compared to controls (SAL vs. 15 days
LPS p = 0.050) (Fig. 5a, c). At this time point, the
PDGFRa+ progenitor and precursor oligodendrocyte
populations tended to decrease compared to controls
(SAL vs. 15 days LPS p = 0.070) (Fig. 5a, d). No signifi-
cant changes of CNPase+ cells and MBP IR were found
following LPS exposure compared to controls at all stud-
ied time points (Fig. 5a, e, f ).
Table 1 MPO-positive cells in the choroid plexus and white matter
MPO+ cells/mm2 SAL 5 hours LPS 12 hours LPS 24 hours LPS 2 days LPS 4 days LPS 8 days LPS 15 days LPS
Choroid plexus 2.44 ± 3.22 4.34 ± 2.86 3.19 ± 3.44 1.80 ± 1.45 3.88 ± 2.54 6.25 ± 4.25 4.07 ± 2.67 3.51 ± 4.38
White matter 0.47 ± 0.30 3.83 ± 3.82 1.14 ± 0.83 1.95 ± 2.46 1.88 ± 2.70 2.05 ± 1.84 2.67 ± 2.50 4.52 ± 4.22*
Mean values ± standard deviations are represented
*p < 0.05
Fig. 4 Intra-amniotic exposure to LPS results in a decrease in mitotic cells and relatively late onset of cell death in the preterm white matter and
hippocampus. A significant increase of caspase-3-positive cells is observed at 8 days following LPS exposure in the white matter compared to
controls (SAL vs 8 days LPS p = 0.004) (a). In the hippocampus, at 2, 4, 8, and 15 days following LPS exposure an increase in caspase-3-positive
cells was found compared to controls (SAL vs 2 days LPS p = 0.002; SAL vs 4 days LPS p = 0.030; SAL vs 8 days LPS p = 0.058; SAL vs 15 days LPS
p = 0.042) (b). At 2 days following LPS exposure, a decrease in pHH3+ cells was found compared to controls (SAL vs. 2 days LPS p = 0.100) (c).
Caspase-3 and pHH3 are expressed as positive cells/mm2 and represented in the graphs as mean ± 95% CI. Asterisk indicated p < 0.05 versus
control (SAL); number sign indicated 0.05 < p < 0.1 versus control (SAL)
Gussenhoven et al. Journal of Neuroinflammation  (2018) 15:113 Page 6 of 13
Intra-amniotic exposure to LPS resulted in altered dendritic
development in gray matter regions of the fetal brain
Besides alterations in white matter development and
oligodendrocyte loss, developmental disturbances of
the gray matter are an increasingly important feature of
perinatal brain injury [37–39]. For the assessment of
dendritic maturation, we have studied MAP-2 IR as an
established marker for neuronal development [40] in
the hippocampus and cerebral cortex. As illustrated in
Fig. 5, intra-amniotic exposure to LPS results in a sig-
nificant or trend to increase in the MAP-2 IR in the
hippocampus at all time points except at 2 days LPS
(SAL vs 5 h LPS p = 0.007; SAL vs 12 h LPS p = 0.073;
SAL vs 24 h LPS p = 0.000; SAL vs 4 days LPS p = 0.
034; SAL vs 8 days LPS p = 0.000; SAL vs 15 days LPS
p = 0.057) (Fig. 6a, b). At 2 days following LPS expos-
ure, MAP-2 IR is comparable to controls (SAL vs 2 days
LPS p = 0.825). In the cerebral cortex only at 24 h after
LPS exposure, an increase in MAP-2 IR was found
(SAL vs 24 h LPS p = 0.036) (Fig. 6a, c) and all other
time points were comparable to control.
Expression of the phosphorylated erythropoietin receptor
decreases 2 days following LPS exposure
There is a single EPO receptor and activation of this re-
ceptor leads to receptor phosphorylation and as such
phosphorylation is a useful surrogate for EPO-induced
downstream pathway activation. Analysis of the IR for
total EPOR revealed no change from baseline levels at
any of time points of LPS exposure. Interestingly,
Fig. 5 Intra-amniotic exposure to LPS induces distinct time-dependent changes in oligodendrocyte lineage cells. A significant decrease of Olig2-positive
cells was observed in animals after 15 days of LPS exposure compared to controls (SAL vs. 15 days LPS p= 0.050) (c). At the same time point, a decrease in
PDGFRa-positive cells was found compared to controls (SAL vs. 15 days LPS p= 0.070) (d). No significant changes of CNPase+ cells were found following
LPS exposure compared to controls (e). Area fractions (%) of MBP immunoreactivity (IR) showed a decrease at 2 days and an increase at 8 days following
LPS exposure compared to controls (SAL vs. 2 days LPS, p= 0.070; SAL vs. 8 days LPS p= 0.083) (f). Representative histological figures of Olig2, PDGFRa, and
CNPase-positive cells and MBP IR in animals exposed to intra-amniotic saline (SAL) and 15 days of LPS are shown in a and b respectively. Images taken at
× 100 magnification (insert at × 400 magnification), scale bar = 200 μm. Asterisk indicated p< 0.05 versus control (SAL); number sign indicated 0.05 < p<
0.1 versus control (SAL)
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however, we observed that pEPOR had a distinct time-
dependent switch from over-expression to under-
expression. Specifically, following 5 h of LPS exposure
pEPOR IR was significantly increased in the white mat-
ter (SAL vs 5 h p = 0.010) (Fig. 7a, c) and tended to in-
crease in the cortex (SAL vs 5 h p = 0.100) (Fig. 7e)
compared to controls. However, at 2 days after LPS ex-
posure, there is a strong decrease in pEPOR IR within
all brain regions compared to controls: significant in the
white matter (SAL vs 2d LPS p = 0.030) and trending in
the hippocampus (SAL vs 2 days LPS p = 0.088) and cor-
tex (SAL vs 2 days LPS p = 0.010) (Fig. 7c–e). At 4 and
8 days following LPS exposure, pEPOR expression is still
decreased compared to controls, trending in the white
matter (SAL vs 4 days LPS p = 0.100), and significant in
the hippocampus (SAL vs 4 days LPS 0.045; SAL vs
8 days LPS p = 0.014) and cortex (SAL vs 4 days LPS 0.
020.; SAL vs 8 days LPS p = 0.030). When the fetus had
been exposed to 15 days of LPS, there was no drop in
pEPOR IR.
Discussion
The main findings of this study are that intra-amniotic
exposure to LPS results in (1) an acute onset and
biphasic fetal systemic inflammatory response; (2) per-
sisting microgliosis with a limited pro-inflammatory
phase; (3) cell death and (pre) oligodendrocytes loss only
following long exposure to inflammation (8 days +) but
(4) a striking regional sensitivity to changes in neuronal
architecture following short (hours) and long (days) LPS
exposure, and (5) biphasic regulation of pEPOR expres-
sion. We demonstrate that fetuses, intra-amniotically ex-
posed to LPS, develop biphasic opposing peaks in the
systemic inflammatory response, illustrated by changes
in IL-6 and IL-8 concentrations. This data agree with
previous observations from this model on increased cir-
culatory monocytes and neutrophils and subsequent
lymphocytopenia [4] and agrees with previous clinical
data showing increased levels of these cytokines, associ-
ated with adverse neurological outcomes [41, 9].
Furthermore, the systemic response to LPS is consist-
ently associated with the production of a vast milieu of
inflammatory cytokines including IL-6 [42]. These sig-
nals across the blood-brain barrier trigger a neuroin-
flammatory response including activation of microglia
and astrocytes [6, 5]. Moreover, IL-8 is known as potent
chemotactic and neutrophil-activating factor, and in-
creased serum IL-8 levels are reported in newborns with
Fig. 6 Intra-amniotic exposure to LPS results in altered dendritic development in the gray matter of the fetal brain. A significant increase of the
area fraction (%) of MAP-2 immunoreactivity (IR) was found in the cerebral cortex at 24 h after LPS exposure compared to controls (SAL vs 24 h
LPS p = 0.036) (a, c). In the hippocampus, an increase of area fraction (%) of MAP-2 IR was observed at 5, 12, and 24 h and at 4, 8, and 15 days
after LPS exposure compared to controls (SAL vs 5 h LPS p= 0.007; SAL vs 12 h LPS p= 0.073; SAL vs 24 h LPS p= 0.000; SAL vs 4 days LPS p= 0.034; SAL
vs 8 days LPS p= 0.000; SAL vs 15 days LPS p= 0.057) (b, d). Representative histological figures of MAP-2 in the cerebral cortex (a) and hippocampus (b)
are depicted in control animals (SAL) and animals exposed to LPS for 24 h, 2 days, and 8 days. Images taken at × 100 magnification (insert at
× 400 magnification), scale bar = 200 μm. Asterisk indicated p < 0.05 versus control (SAL); number sign indicated 0.05 < p < 0.1 versus control (SAL)
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MRI-defined cerebral abnormalities and abnormal neu-
rodevelopmental outcomes [43, 44, 9, 45, 46]. In line, we
observed an increased number of MPO+ cells within the
cerebral white matter at 15 days after LPS exposure.
Our study also provides meaningful information about
the cerebral inflammatory response initiated by intra-
amniotic LPS exposure. We observed a rapid increase in
the inflammatory mediator COX-2 and microglial
marker IBA-1 in the preterm brain. COX-2 activity re-
sults in prostaglandin-E2 production which has wide
ranging inflammatory actions on the brain [47], but is
typically associated with a pro-inflammatory state in
microglia [48] and also reported in astrocytes [49].
Weaver-Mikaere et al. demonstrated in a fetal ovine-
derived mixed glial culture that COX-2 activation is the
most important mechanism leading to inflammation-
mediated white matter injury [50]. Blocking the COX-2
pathway has recently been shown to prevent hypomyeli-
nation and behavioral impairment in mice with neonatal
white matter injury [49]. In this model, it has also been
reported that there is also no change in GFAP-IR across
the groups, but additional analysis revealed that despite
this, astrocytes together with microglia were still an im-
portant source of oligodendrocyte-injurious COX-2 [49].
An additional injurious mechanism of increased COX-2
is that its primary product prostaglandinE2 stimulates
Fig. 7 Expression of the phosphorylated erythropoietin receptor decreases 2 days following LPS exposure. An acute increase of the area fraction
(%) of pEPOR immunoreactivity (IR) was observed at 5 h after LPS exposure in the white matter (SAL vs 5 h p = 0.010) and cortex (SAL vs 5 h p = 0.100)
compared to controls (c, e). At 2 days after LPS exposure, there is a significant decrease in pEPOR IR within all brain regions compared to controls:
white matter (SAL vs 2 days LPS p = 0.030) (c), hippocampus (SAL vs 2 days LPS p = 0.088) (d), and cortex (SAL vs 2 days LPS p = 0.010) (e). At 4 and
8 days following LPS exposure, pEPOR expression is still decreased compared to controls in the white matter (SAL vs 4 days LPS p= 0.100), hippocampus
(SAL vs 4 days LPS 0.045; SAL vs 8 days LPS p = 0.014), and cortex (SAL vs 4 days LPS 0.020.; SAL vs 8 days LPS p = 0.030). When the fetus had
been exposed to 15 days of LPS, there was no decrease in pEPOR IR (c–e). Representative histological figures of the pEPOR in the white matter (a) and
hippocampus (b) are depicted in control animals (SAL) and animals exposed to LPS for 5 h, 2 days, and 15 days. Images taken at × 100 magnification
(insert at × 400 magnification), scale bar = 200 μm. Asterisk indicated p< 0.05 versus controls (SAL), number sign indicated 0.05 < p<0.1 versus controls (SAL)
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glutamate release from astrocytes [51], which is
suggested to be essential in the pathophysiological
mechanism underlying neonatal encephalopathy [52].
Additionally, the dynamic temporal microglial response
in our inflammatory model, indicated by increased
IBA-1IR, is consistent with distinct phases of cerebral
inflammation in response to other injurious factors in
perinatal brain injury, including a hypoxic-ischemic or
excitotoxic insult [9]. Microglial activation is proposed
to be essential in cerebral injury and dysmaturation as-
sociated with exposure to maternal fetal infection/in-
flammation [53]. Of interest for the application of
neurotherapeutics is that microglia activation based on
the simple proxy of IBA-1IR was maintained for at least
8 days following LPS exposure, but increased COX2 as
surrogate for a pro-inflammatory state was only elevated
for 1 day. Further studies to determine a systemic surro-
gate of microglial activation state might re-invigorate the
utility of previously discarded immunomodulatory neu-
rotherapeutics if we understood when immunosuppres-
sion would be beneficial.
Considerable debate has raged in the field of preterm
neuropathology regarding the role for cell death in en-
cephalopathy of prematurity [54–57]. Experimental data
has shown that microglia activation results in pro-
inflammatory cytokine release which in turn can lead to
apoptosis. However, experimental data has also demon-
strated that moderate activation of microglia leads only
to the maturation arrest of oligodendrocytes and not cell
death [58]. Our study supports a coherent integration of
clinical and experimental data as it shows that with a
clinically relevant exposure paradigm, the duration of
exposure is essential; oligodendrocyte death only occurs
after 8 days of LPS exposure. Although outside the scope
of this study, research into additional variables including
pathogen type and maternal/fetal health and genetics
also undoubtedly play a role understanding cohort-
specific observations on neuropathology. We also wish
to highlight that the significant loss of (pre) oligodendro-
cytes was not accompanied by myelin loss in our study.
It has been previously postulated that the type of robust
reduction in myelin protein levels that we would be able
to measure with our analysis technique only occurs later
in the course of brain injury due to normal kinetics of
myelin production [59]. Furthermore, in an
inflammation-induced oligodendrocyte injury model,
early analysis of myelin proteins [58] and genes [60] has
indeed failed to observe reductions despite later robust
hypomyelination and behavioral deficits. Detailed ana-
lysis of myelin structure could be considered to investi-
gate early markers of myelin injury in future studies.
Together with disturbed white matter development, al-
terations in gray matter development are implicated in
long-term neurological sequelae following intra-amniotic
infections and preterm birth [39, 37, 38]. During normal
gray matter development, a decrease in MAP-2IR occurs
which is indicative for refining of dendritic branching
and spines [40]. Regulation of spine development is part
of the basic homeostatic functions of microglia, which
also include supporting immature cortical neuronal sur-
vival and stimulating myelination [61]. As such, increase
in MAP-2 IR that we found in the acute phase following
LPS exposure suggests a delay in cortical development, a
phenomenon that has also been suggested from analysis
of preterm infants using MRI [62]. Moreover, in humans
suffering from schizophrenia, increased dendritic
arborization was found in the hippocampus compared to
healthy humans when stained for MAP-2 [63]. Concern-
ing the specific mechanistic link between increased in-
flammation and increased MAP-2, it is noteworthy that
COX-2 overexpressing neuronal-like cells showed sig-
nificantly increased neurite outgrowth and branching,
which was partially reverted by COX inhibitor [64].
Despite multiple studies identifying EPO as very prom-
ising neuroprotective candidate in newborn infants [65,
66, 14, 67, 13, 17, 68–70], other studies did not find
therapeutic effects on neurodevelopmental outcomes
[71, 72, 23]. These inconsistencies might be explained by
heterogeneity between study cohorts including, as out-
lined in this study for the first time, differences in EPO
signaling in response to inflammation. Interestingly, after
an initial increase in the receptor phosphorylation levels,
a distinct and long-lasting decrease of the pEPOR oc-
curred. Activation of the EPOR phosphorylates activates
the kinase Jak-2 resulting in initiation of a complex anti-
apoptotic signaling cascade [73, 25]. Accordingly, we are
unsurprised that a decrease in the level of pEPOR is ac-
companied by an increase in the number of apoptotic
cells (caspase-3+) within the same region in the fetal
brain. This suggests that the reduced activation of the
EPO receptor in our study results in increased apoptosis
in the preterm brain and in experimental paradigms this
relationship between EPOR and cell death has been
demonstrated [25]. In regards to the total expression of
EPOR, others have also shown that this remains stable
or increases [74], and this elevation occurs within hours
in response to pro-inflammatory cytokines like TNFa
[75], whereas the level of its parent ligand, EPO, is
downregulated under pro-inflammatory conditions [76].
Thus, understanding the inflammation-induced dysregu-
lation of EPO signaling provides a therapeutic window
where treatment with EPO may be most efficacious [76].
Altogether, the considerable changes in EPOR expres-
sion within the fetal brain in the course of inflammation
stresses the need for biomarkers to determine the onset
of intra-amniotic infections.
One important limitation of a large animal study is the
relatively low number of animals per group. Given the
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relatively small animal numbers per group, we reported
actual p values and tended to interpret p values between
0.05 and 0.1 as biologically relevant. This assumption
decreases the chance of a false-negative finding but in-
creases the chance that one of these differences is a
false-positive result.
Conclusion
Altogether, the cerebral changes as found in our transla-
tional model of inflammation-related brain injury of the
preterm infant could be reasonably expected to lead to
deficits in learning, memory and social skills, and/or
motor disabilities that can persist into adulthood [34].
However, these outcomes need to be confirmed in longi-
tudinal studies, incorporating behavioral analysis and MRI
but nonetheless inform the development of interventions
to protect and/or regenerate the preterm brain in order to
allow normal development. By gaining more insight into
the temporal processes underlying inflammation-induced
preterm brain injury, we provide an increased understand-
ing of the pathophysiological changes in the fetal brain
with the goal of helping to design new interventions or
implement interventions more effectively to prevent peri-
natal brain damage.
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